Barcelona Institute for Global Health

Insud Pharma Receives $2.7M Grant to Develop Sublingual Oxytocin for Postpartum Hemorrhage

6 months ago

• Insud Pharma has been awarded a $2.7 million grant from the Bill & Melinda Gates Foundation to advance a sublingual oxytocin treatment for postpartum hemorrhage (PPH). • The Phase II clinical trial, set to begin in early 2025, will involve 180 participants to determine the optimal dosage of the sublingual oxytocin. • The sublingual oxytocin tablet is thermostable, eliminating the need for refrigeration and specialized healthcare personnel, making it suitable for low-resource settings. • Postpartum hemorrhage affects approximately 14 million women globally each year and is a leading cause of maternal mortality, especially in low- and middle-income countries.

Insud Pharma and Gates Foundation Partner to Develop Sublingual Oxytocin for Postpartum Hemorrhage Prevention

6 months ago

• Insud Pharma receives $2.7 million from the Bill & Melinda Gates Foundation to advance a sublingual oxytocin formulation for preventing postpartum hemorrhage (PPH). • The Phase II clinical trial will determine the optimal dose of the thermostable sublingual oxytocin, which doesn't require refrigeration or skilled personnel for administration. • The collaboration aims to reduce maternal mortality, particularly in low- and middle-income countries where PPH is a leading cause of death, affecting approximately 14 million women annually. • Mundo Sano Foundation will support awareness campaigns and facilitate access to the treatment in underserved regions, promoting equitable healthcare access.